| Valid Data Submission Method(s) | Measure Type | High Priority Measure? | NQS Domain | Specialty Measure Sets |
|---|---|---|---|---|
| Registry | Process | Yes | Patient Safety | General Oncology |
Measure Description
Percentage of adult patients (aged 18 or over) with metastatic colorectal cancer and KRAS gene mutation spared treatment with anti-EGFR monoclonal antibodies
Instruction
This measure is to be reported once per performance period for patients with colorectal cancer seen during the performance period. This measure may be reported by eligible clinicians who perform the quality actions described in the measure based on the services provided and the measure-specific denominator coding.
Denominator
Adult patients with metastatic colorectal cancer who have a KRAS gene mutation
Definition:
KRAS mutation testing– KRAS testing for this measure refers to assays that detect mutations in codons 12 and 13 of KRAS only. Do not include results from mutations at other codons (e.g., codons 61 and 146), or assays for other alterations (e.g., BRAF, PI3K, PTEN genes). The College of American Pathologists (CAP) Perspectives on Emerging Technology (POET) Report on KRAS mutation testing provides additional guidance on testing.
If multiple KRAS mutation tests have been performed, refer to the most recent test results.
Denominator Criteria (Eligible Cases):
Patients aged ≥ 18 years on date of encounter
AND
Diagnosis of colon or rectal cancer (ICD-10 CM): C18.0, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20
AND
Patient encounter during the performance period: 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215
AND
Two or more encounters at the reporting site
AND
Patient has metastatic disease at diagnosis: G9842
AND
KRAS gene mutation: G9843
Numerator
Anti-EGFR monoclonal antibody therapy not received
Definition:
Anti-EGFR monoclonal antibody– cetuximab or panitumumab
Numerator Options:
Performance met: Patient did not receive anti-EGFR monoclonal antibody therapy (G9844)
OR
Performance Not Met: Patient received anti-EGFR monoclonal antibody therapy (G9845)